Table 2.

Frequency of kinase alterations

SubgroupNCI high risk (n = 884), n (%)NCI standard risk, (n = 505), n (%)Total (n = 1389), n (%)P, high vs standard risk*
Ph-like ALL198 (22.4)86 (17.0)284 (20.4).019
CRLF2 rearrangement96 (10.9)29 (5.7)125 (9.0).0012
 IGH-CRLF256 (6.3)5 (1.0)61 (4.4)<.001
 P2RY8-CRLF240 (4.5)24 (4.8)64 (4.6).89
CRLF2 rearrangement with JAK-STAT mutation46 (5.2)17 (3.4)63 (4.5).14
CRLF2 rearrangement without JAK-STAT mutation50 (5.7)12 (2.4)62 (4.5).0043
Non-CRLF2102 (11.5)57 (11.3)159 (11.4).93
 ABL1-class fusions35 (4.0)5 (1.0)40 (2.9).0012
 JAK2 rearrangement9 (1.0)5 (1.0)14 (1.0).99
 EPOR rearrangement11 (1.2)0 (0)11 (0.8).0095
 Other kinase7 (0.8)6 (1.2)13 (0.9).56
 Other JAK-STAT§12 (1.4)6 (1.2)18 (1.3).99
 Ras6 (0.7)11 (2.2)17 (1.2).021
 No kinase identified18 (2.0)24 (4.8)42 (3.0).0055
  • * Fisher’s exact test.

  • ABL1-class: ABL1, ABL2, CSF1R, PDGFRB.

  • Other kinase: NTRK3, LYN, FLT3.

  • § Other JAK-STAT: IL7R, SH2B3, JAK1.